HBM Holdings (FRA:6XY) Pre-Tax Income : €3.53 Mil (TTM As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is HBM Holdings Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. HBM Holdings's pretax income for the six months ended in Jun. 2024 was €1.60 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2024 was €3.53 Mil. HBM Holdings's pretax margin was 7.28%.

During the past 7 years, HBM Holdings's highest Pretax Margin was 25.34%. The lowest was -3199.38%. And the median was -1675.00%.

HBM Holdings Pre-Tax Income Historical Data

The historical data trend for HBM Holdings's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings Pre-Tax Income Chart

HBM Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Pre-Tax Income

Get a 7-Day Free Trial

-243.84

-121.98

-129.35

20.80

3.57

HBM Holdings Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial								-60.58	2.68	18.14	1.60	1.92

Competitive Comparison of HBM Holdings's Pre-Tax Income

For the Biotechnology subindustry, HBM Holdings's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HBM Holdings's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HBM Holdings's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where HBM Holdings's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

HBM Holdings Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

HBM Holdings's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	20.786	+	0	+	-3.551	+	5.157	+	-1.593
	=	20.80

HBM Holdings's Pretax Income for the quarter that ended in Jun. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-0.19	+	0	+	-1.448	+	0	+	3.24
	=	1.60

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €3.53 Mil.

HBM Holdings (FRA:6XY) Pre-Tax Income Explanation

HBM Holdings's Pretax Margin for the quarter that ended in Jun. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	1.602	/	22.018
	=	7.28%

During the past 7 years, HBM Holdings's highest Pretax Margin was 25.34%. The lowest was -3199.38%. And the median was -1675.00%.

HBM Holdings Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of HBM Holdings's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

HBM Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (FRA:6XY) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

HBMHF:USA 02142:Hong Kong

Address

218 Xinghu Street, Suite 202, Building A3, Suzhou Industrial Park, Suzhou, CHN, 215123

Website

https://www.harbourbiomed.com

HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.

HBM Holdings Headlines

No Headlines